LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data

Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial

“…In clinical trials in patients with atopic dermatitis, asthma or chronic sinusitis with nasal polyposis, dupilumab demonstrated efficacy and an acceptable safety profile. In a phase IIa randomized, double‐blind, placebo‐controlled trial enrolling adults with moderate‐to‐severe atopic dermatitis inadequately controlled by topical medications, 12 weeks of treatment with subcutaneous dupilumab 300 mg weekly significantly improved clinical outcomes compared with placebo, including Eczema Area and Severity Index (EASI) score, percentage of body surface area (BSA) affected with atopic dermatitis, pruritus numerical rating scale (NRS) score, proportion of patients achieving a reduction of ≥ 50% or ≥ 75% in EASI score (EASI 50, EASI 75), and the proportion of patients with an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear).…”